Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technology
Biotech firm Factor Bioscience has filed a lawsuit against Cellectis and AstraZeneca, accusing the companies of allegedly infringing three patents related to its gene-editing technology used in cancer treatments. The lawsuit, filed in the District federal Court, alleges that Cellectis copied Factor’s technology for designing gene-edited cells for cancer therapies. Cellectis licenses its gene-editing technology to AstraZeneca for research and development. For Factor: Robert Cerwinski, Michael Johnson and Lora Green of Gemini Law; Huiya Wu and Linnea Cipriano of Goodwin Procter For Cellectis and AstraZeneca: attorney information not yet available
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!